Forbion Capital Partners
Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.
Business Model:
Revenue: $0
Employees: 2-10
Rankings
Industries / Tags:
Detailed Forbion Capital Partners Information
Geographic Data
Address: PO Box 5187
City: Naarden
State: flevoland
Zip: 1410
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Twitter
Linkedin
Crunchbase
Metrics
8,335,511Website Global Rank
447Website Monthly Traffic
Twitter Followers
Description
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion&s;s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2015 | Insmed | Post-IPO Equity | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 1/2021 | Complement Therapeutics | Seed Round | - |
| 7/2017 | Exosome Diagnostics | Series C | 0 |
| 11/2011 | CircuLite | Series D | 30M |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 12/2013 | Ario Pharma | Seed Round | 3.1M |
| 3/2014 | Exosome Diagnostics | Series B | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 4/2012 | Argos Therapeutics | Series D | 0 |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 1/2016 | Exosome Diagnostics | Series B | 0 |
| 1/2021 | New Amsterdam Pharma | Series A | 0 |
| 6/2010 | Cytheris | Series D | 15M |
| 3/2010 | Promedior | Series C | 12M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2013 | UniQure | Private Equity Round | 0 |
| 4/2007 | CircuLite | Series B | 5M |
| 1/2010 | CircuLite | Series C | 32.5M |
| 9/2009 | arGEN-X | Series A | 13.6M |
| 8/2007 | AM Pharma | Series C | 3.4M |
| 9/2011 | Amakem | Series A | 25.2M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 3/2005 | Borean Pharma | Series A | 0 |
| 11/2013 | Argos Therapeutics | Series E | 0 |
| 7/2005 | Xention | Series B | 13.3M |
| 10/2001 | Ardana Bioscience | Series A | 20M |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 6/2015 | Realeve | Series D | 43.2M |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 6/2019 | SANIFIT | Series D | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 1/2011 | PneumRx | Venture Round | 0 |
| 3/2008 | PanGenetics | Series C | 35.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 11/2021 | Prilenia | Series B | 0 |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 9/2017 | Replimune Group | Series B | 55M |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 9/2015 | SANIFIT | Series C | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 7/2021 | NeRRe Therapeutics | Series B | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 11/2014 | Curetis | Series B | 0 |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 12/2002 | Transave | Series B | - |
| 9/2015 | Exosome Diagnostics | Series B | 0 |
| 2/2011 | CellNovo | Series B | 48.3M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 2/2013 | Dezima Pharma | Venture Round | 18.6M |
| 1/2021 | CoviCept Therapeutics | Seed Round | 2.3M |
| 9/2015 | Replimune Group | Series A | 30M |
| 9/2005 | Bioceros | Private Equity Round | - |
| 11/2022 | CatalYm | Series C | 0 |
| 3/2021 | Oxular | Series B | 37M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 8/2018 | KaNDy Therapeutics | Series C | 32.6M |
| 2/2016 | Akarna | Series B | 15M |
| 11/2011 | Oxyrane | Series D | 26.5M |
| 7/2011 | gIcare Pharma | Series A | 7.4M |
| 6/2021 | VectorY | Seed Round | 0 |
| 10/2004 | FlowMedica | Series C | 0 |
| 5/2010 | Exosome Diagnostics | Series A | 20M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 11/2006 | Pieris AG | Series B | 0 |
| 8/2009 | NovoGI | Series F | 0 |
| 1/2003 | Impella Cardiosystems | Venture Round | 40M |
| 12/2011 | arGEN-X | Series B | 43.8M |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 6/2020 | Prilenia | Series A | 62.5M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 11/2020 | Catalym | Series B | 59.3M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 3/2012 | Promedior | Series D | 21.5M |
| 10/2012 | Promedior | Series D | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 4/2008 | Transave | Series D | 35M |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 3/2021 | Gyroscope Therapeutics | Series C | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 3/2022 | Precirix | Series B | 0 |
| 3/2015 | Rigontec | Series A | 5.2M |
| 5/2023 | Dualyx | Series A | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 3/2009 | BioVex | Venture Round | 40M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 5/2015 | Replimune Group | Seed Round | 2M |
| 5/2021 | Numab | Series C | 110.6M |
| 9/2016 | Rigontec | Series A | 16.9M |
| 10/2011 | Curetis | Series A | 13.3M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 8/2016 | Catalym | Seed Round | - |
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 11/2018 | Inflazome | Series B | 45.8M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 2/2022 | Complement Therapeutics | Seed Round | 5.7M |
| 11/2018 | OMEICOS Therapeutics | Series C | 0 |
| 3/2018 | Escalier Biosciences | Series B | 19M |
| 1/2015 | enGene | Series B | 0 |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 9/2010 | Cardoz | Series A | 17.6M |
| 4/2023 | Complement Therapeutics | Series A | 0 |
| 3/2023 | Seamless Therapeutics | Seed Round | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 11/2022 | CatalYm | Series C | 0 |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 9/2022 | Pheon Therapeutics | Series A | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 6/2022 | VectivBio | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
